{"id":"16fbbc19102d","type":"article","url":"https://hartvaat.nl/2026/02/05/tenecteplase-versus-standaardbehandeling-bij-basilaris-occlusie-in-the-lancet/","title":"Tenecteplase versus standaardbehandeling bij basilaris-occlusie in The Lancet","title_en":"Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02633-9/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02633-9/fulltext","authors":["Yunyun Xiong","Fana Alemseged","Zhixin Cao","Lee H Schwamm","Si Zhang","Mark W Parsons","Marc Fisher","Yahui Hao","Aoming Jin","Jinfeng Yin","Yong Jiang","Fengyuan Che","Lihua Wang","Li Zhou","Hongguo Dai","Yutie Zhao","Chunmiao Duan","Shuangzhe Wu","Ganghua Feng","Lixia Zong","Wanxing Ye","Ziran Wang","Ziqi Xu","Hao Wang","Manjun Hao","Yujie Ma","Xia Meng","Hao Li","Zixiao Li","Yilong Wang","Liping Liu","Xingquan Zhao","Bruce C V Campbell","Yongjun Wang","TRACE-5 investigators"],"significance":9,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/ischemische-beroerte-tia/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"The TRACE-5 trial demonstrated that intravenous tenecteplase within 24 hours improved functional outcomes in Chinese patients with ischemic stroke due to basilar artery occlusion. The results support thrombolysis as an effective treatment for this devastating posterior circulation stroke subtype.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De TEMPO-2 trial, gepubliceerd in The Lancet, toont dat intraveneuze tenecteplase veilig en effectief kan zijn bij patiënten met een basilaris-occlusie tot 24 uur na het begin van symptomen. Dit opent de deur voor een bredere toepassing van trombolyse bij deze ernstige vorm van herseninfarct.","abstract_original":"In this trial involving Chinese patients with ischaemic stroke due to basilar artery occlusion, tenecteplase within 24 h after stroke onset improved functional outcome compared with standard medical treatment. The incidence of symptomatic intracranial haemorrhage and death was similar."}